Company Profile

Jennerex, Inc.

One Market Street
Spear Tower, Suite 2260
San Francisco California 94105 U.S.A.
Phone: 415-281-8886 Fax:

Industry
Biotechnology
Biopharmaceutical

Segment
Research and Development

Company News

SillaJen Biotherapeutics Announces Completion Of Name Change Following Acquisition Of Jennerex, Inc. 6/19/2014 10:38:27 AM

SillaJen Grabs Jennerex, Inc. for $150 Million 11/26/2013 6:53:02 AM

Jennerex, Inc. Announces That Its Phase 2 Study of Pexa-Vec in Second-Line Advanced Liver Cancer Did Not Meet Its Primary Endpoint 9/3/2013 2:08:23 PM

Jennerex, Inc. to Present at the 33rd Annual Canaccord Genuity Growth Conference 8/12/2013 6:46:56 AM

TRANSGENE (TRGNY) Announces a Follow-on Investment in Jennerex, Inc. 5/28/2013 9:51:16 AM

Jennerex, Inc. Completes $21.6 Million Private Placement 5/23/2013 7:30:07 AM

Jennerex, Inc. Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer 5/21/2013 11:16:33 AM

Jennerex, Inc. Announces Science Translational Medicine Publication Highlighting Pexa-Vec's Ability to Induce Functional Anti-Cancer Immunity in Patients With Diverse Tumor Types 5/16/2013 12:10:12 PM

Jennerex, Inc. Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC) 5/9/2013 11:03:16 AM

Jennerex, Inc. Announces Presentation of Data Demonstrating Pexa-Vec's Vascular Targeting Mechanism 4/9/2013 11:41:49 AM

//-->